Back to Market返回行情

OFIX Orthofix Medical Inc.

USHealthcare
$11.63+1.31%ClosedMarket Cap: $470.1M

As of 2026-07-10 16:00

Why OFIX matters now

Orthofix Medical Inc. (OFIX) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.63 with +1.31% on the session and $470.1M in market capitalization; recent performance reads 1-month -21.84% and YTD -37.66%.

The latest financial table shown here is Q1 2026, with revenue of $196.7M, net income of $-20.9M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.0%.

The latest indexable market news headline is "Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $15.00; recent insider activity includes Paolucci Michael E filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.88

P/S

0.46

EV/EBITDA

5.25

DCF Value

$-91.53

FCF Yield

-1.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

69.0%

Operating Margin

-4.0%

Net Margin

-7.3%

ROE

-13.4%

ROA

-6.8%

ROIC

-4.6%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$196.7M$-20.9M$-0.52
Q4 2025$219.9M$-2.2M$-0.06
FY 2025$822.3M$-92.2M$-2.28
Q3 2025$205.6M$-22.8M$-0.57

Analyst Ratings

Consensus

Hold

Target (Consensus)

$15.60

Target (Median)

$15.00

Target Range

$12.00 - $18.00

Strong Buy: 1Buy: 2Hold: 2Sell: 0Strong Sell: 0
Barrington ResearchOutperform
2026-05-22
StifelBuy
2026-05-22
Canaccord GenuityBuy
2026-05-22
Barrington ResearchOutperform
2026-04-10
StifelBuy
2026-03-09

Trading Activity

Insider Trades

Paolucci Michael Edirector
Sell2026-06-12
Maniar Shwetadirector
Sell2026-06-12
BURRIS WAYNEdirector
Sell2026-06-12
HENNEMAN JOHN B IIIdirector
Sell2026-06-12
CAPPS VICKIE Ldirector
Sell2026-06-12

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.71

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.